{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:00:52Z","timestamp":1790168452605,"version":"4.1.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04305-9","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:32:40Z","timestamp":1776108760000},"page":"4277-4296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of borderline resectable NSCLC: a narrative review"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0985-6150","authenticated-orcid":false,"given":"Xabier","family":"Mielgo-Rubio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Aso Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eider","family":"Azkona Uribelarrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bolufer Nadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Calvo De Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Mart\u00edn Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Navarro-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"L\u00f3pez Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Provencio Pulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Trujillo Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Cou\u00f1ago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"4305_CR1","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","volume":"383","author":"N Howlader","year":"2020","unstructured":"Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383:640\u20139.","journal-title":"N Engl J Med"},{"key":"4305_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"4305_CR3","doi-asserted-by":"publisher","first-page":"102693","DOI":"10.1016\/j.canep.2024.102693","volume":"93","author":"J Zhou","year":"2024","unstructured":"Zhou J, Xu Y, Liu J, Feng L, Yu J, Chen D. Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol. 2024;93:102693.","journal-title":"Cancer Epidemiol"},{"key":"4305_CR4","unstructured":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica (SEOM) (2026). Las cifras del c\u00e1ncer en Espa\u00f1a 2026."},{"key":"4305_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.21037\/tlcr.2020.03.40","volume":"10","author":"A Casal-Mouri\u00f1o","year":"2021","unstructured":"Casal-Mouri\u00f1o A, Ruano-Ravina A, Lorenzo-Gonz\u00e1lez M, Rodr\u00edguez-Mart\u00ednez \u00c1, Giraldo-Osorio A, Varela-Lema L, et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021;10:506\u201318.","journal-title":"Transl Lung Cancer Res"},{"key":"4305_CR6","doi-asserted-by":"publisher","first-page":"461","DOI":"10.21037\/tlcr.2019.08.05","volume":"8","author":"M Provencio","year":"2019","unstructured":"Provencio M, Carcereny E, Rodr\u00edguez-Abreu D, L\u00f3pez-Castro R, Guirado M, Camps C, et al. Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). Transl Lung Cancer Res. 2019;8:461\u201375.","journal-title":"Transl Lung Cancer Res"},{"key":"4305_CR7","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non\u2013Small Cell Lung Cancer. Version 3.2026. December 24, 2025. Fort Washington, PA: NCCN; 2025. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf"},{"key":"4305_CR8","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jtho.2024.02.011","volume":"19","author":"R Rami-Porta","year":"2024","unstructured":"Rami-Porta R, Nishimura KK, Giroux DJ, Detterbeck F, Cardillo G, Edwards JG, et al. The international association for the study of lung cancer lung cancer staging project: proposals for revision of the TNM stage groups in the forthcoming (Ninth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2024;19:1007\u201327.","journal-title":"J Thorac Oncol"},{"key":"4305_CR9","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1200\/OP-24-00784","volume":"21","author":"N Singh","year":"2025","unstructured":"Singh N, Fr\u00fch M, Gubens MA, Ismaila N, Daly ME. Management of Stage III Non\u2013Small Cell Lung Cancer: ASCO guideline rapid recommendation update clinical insights. JCO Oncol Pract. 2025;21:463\u20136.","journal-title":"JCO Oncol Pract"},{"key":"4305_CR10","doi-asserted-by":"publisher","first-page":"108061","DOI":"10.1016\/j.lungcan.2024.108061","volume":"199","author":"I Houda","year":"2025","unstructured":"Houda I, Bahce I, Dickhoff C, Kroese TE, Kroeze SGC, Mariolo AV, et al. An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer. Lung Cancer. 2025;199:108061.","journal-title":"Lung Cancer"},{"key":"4305_CR11","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","volume":"21","author":"M Provencio","year":"2020","unstructured":"Provencio M, Nadal E, Insa A, Garc\u00eda-Campelo MR, Casal-Rubio J, D\u00f3mine M, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:1413\u201322.","journal-title":"Lancet Oncol"},{"key":"4305_CR12","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2215530","volume":"389","author":"M Provencio","year":"2023","unstructured":"Provencio M, Nadal E, Gonz\u00e1lez-Larriba JL, Mart\u00ednez-Mart\u00ed A, Bernab\u00e9 R, Bosch-Barrera J, et al. Perioperative nivolumab and chemotherapy in stage III non\u2013small-cell lung cancer. N Engl J Med. 2023;389:504\u201313.","journal-title":"N Engl J Med"},{"key":"4305_CR13","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973\u201385.","journal-title":"N Engl J Med"},{"key":"4305_CR14","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee H, Liberman M, Kato T, Tsuboi M, Lee S-H, Gao S, et al. Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer. N Engl J Med. 2023;389:491\u2013503.","journal-title":"N Engl J Med"},{"key":"4305_CR15","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.1200\/JCO.2024.42.16_suppl.8011","volume":"42","author":"J Heymach","year":"2024","unstructured":"Heymach J, Reck M, Mitsudomi T, Taube JM, Spira AI, Chaft JE, et al. Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): an exploratory subgroup analysis of AEGEAN. J Clin Oncol. 2024;42:8011\u20138011.","journal-title":"J Clin Oncol"},{"key":"4305_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2213-2600(24)00269-8","volume":"13","author":"D Yue","year":"2025","unstructured":"Yue D, Wang W, Liu H, Chen Q, Chen C, Liu L, et al. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial. Lancet Respir Med. 2025;13:119\u201329.","journal-title":"Lancet Respir Med"},{"key":"4305_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jama.2023.24735","volume":"331","author":"S Lu","year":"2024","unstructured":"Lu S, Zhang W, Wu L, Wang W, Zhang P, Fang W, et al. Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer. JAMA. 2024;331:201.","journal-title":"JAMA"},{"key":"4305_CR18","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jtho.2024.06.010","volume":"19","author":"JD Spicer","year":"2024","unstructured":"Spicer JD, Cascone T, Wynes MW, Ahn M-J, Dacic S, Felip E, et al. Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the International Association for the Study of Lung Cancer. J Thorac Oncol. 2024;19:1373\u2013414.","journal-title":"J Thorac Oncol"},{"key":"4305_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/med4.7","volume":"1","author":"Y Wu","year":"2023","unstructured":"Wu Y, Lu S, Zhou Q, Zhang L, Cheng Y, Wang J, et al. Expert consensus on treatment for stage III non-small cell lung cancer. Med Adv. 2023;1:3\u201313.","journal-title":"Med Adv"},{"key":"4305_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.athoracsur.2024.09.041","volume":"119","author":"SS Kim","year":"2025","unstructured":"Kim SS, Cooke DT, Kidane B, Tapias LF, Lazar JF, Awori Hayanga JW, et al. The society of thoracic surgeons expert consensus on the multidisciplinary management and resectability of locally advanced non-small cell lung cancer. Ann Thorac Surg. 2025;119:16\u201333.","journal-title":"Ann Thorac Surg"},{"key":"4305_CR21","doi-asserted-by":"crossref","unstructured":"Ospina AV, Bolufer Nadal S, Campo-Ca\u00f1averal de la Cruz JL, Gonz\u00e1lez Larriba JL, Mac\u00eda Vidueira I, Massut\u00ed Sureda B, et al (2024) Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP. Clin Trans Oncol 26:1647\u20131663.","DOI":"10.1007\/s12094-024-03382-y"},{"key":"4305_CR22","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage iii non\u2013small-cell lung cancer. J Clin Oncol. 2022;40:1301\u201311.","journal-title":"J Clin Oncol"},{"key":"4305_CR23","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1200\/JCO.19.01162","volume":"38","author":"JD Bradley","year":"2020","unstructured":"Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE, et al. Long-term results of NRG oncology RTOG 0617: standard-versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non\u2013small-cell lung cancer. J Clin Oncol. 2020;38:706\u201314.","journal-title":"J Clin Oncol"},{"key":"4305_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.athoracsur.2024.01.024","volume":"118","author":"EG Dunne","year":"2024","unstructured":"Dunne EG, Fick CN, Isbell JM, Chaft JE, Altorki N, Park BJ, et al. The emerging role of immunotherapy in resectable non-small cell lung cancer. Ann Thorac Surg. 2024;118:119\u201329.","journal-title":"Ann Thorac Surg"},{"key":"4305_CR25","doi-asserted-by":"publisher","first-page":"115426","DOI":"10.1016\/j.ejca.2025.115426","volume":"221","author":"C Aigner","year":"2025","unstructured":"Aigner C, Baldes N, Begic M, Doerr F, Hoda MA, B\u00f6l\u00fckbas S. Current perspective on resectability in stage III locally advanced NSCLC\u2014the thoracic surgeons\u2019 view. Eur J Cancer. 2025;221:115426.","journal-title":"Eur J Cancer"},{"key":"4305_CR26","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","volume":"383","author":"NSCLC Meta-analysis Collaborative Group","year":"2014","unstructured":"NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383:1561\u201371.","journal-title":"Lancet"},{"key":"4305_CR27","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","volume":"26","author":"J-P Pignon","year":"2008","unstructured":"Pignon J-P, Tribodet H, Scagliotti GV, Douillard J-Y, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552\u20139.","journal-title":"J Clin Oncol"},{"key":"4305_CR28","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1097\/JTO.0b013e3181b9ecca","volume":"4","author":"E Lim","year":"2009","unstructured":"Lim E, Harris G, Patel A, Adachi I, Edmonds L, Song F. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol. 2009;4:1380\u20138.","journal-title":"J Thorac Oncol"},{"key":"4305_CR29","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378:1976\u201386.","journal-title":"N Engl J Med"},{"key":"4305_CR30","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jtho.2020.01.017","volume":"15","author":"S Gao","year":"2020","unstructured":"Gao S, Li N, Gao S, Xue Q, Ying J, Wang S, et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2020;15:816\u201326.","journal-title":"J Thorac Oncol"},{"key":"4305_CR31","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1158\/1078-0432.CCR-22-2994","volume":"29","author":"S Rosner","year":"2023","unstructured":"Rosner S, Reuss JE, Zahurak M, Zhang J, Zeng Z, Taube J, et al. Five-year clinical outcomes after neoadjuvant nivolumab in resectable non-small cell lung cancer. Clin Cancer Res. 2023;29:705\u201310.","journal-title":"Clin Cancer Res"},{"key":"4305_CR32","doi-asserted-by":"publisher","first-page":"e005636","DOI":"10.1136\/jitc-2022-005636","volume":"10","author":"M Wislez","year":"2022","unstructured":"Wislez M, Mazieres J, Lavole A, Zalcman G, Carre O, Egenod T, et al. Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO). J Immunother Cancer. 2022;10:e005636.","journal-title":"J Immunother Cancer"},{"key":"4305_CR33","doi-asserted-by":"publisher","unstructured":"Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, et al. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label single-arm phase II trial. Nat Med. 2022;28(10):2155\u201361. https:\/\/doi.org\/10.1038\/s41591-022-01962-5.","DOI":"10.1038\/s41591-022-01962-5"},{"key":"4305_CR34","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1200\/JCO.21.02660","volume":"40","author":"M Provencio","year":"2022","unstructured":"Provencio M, Serna-Blasco R, Nadal E, Insa A, Garc\u00eda-Campelo MR, Casal Rubio J, et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIa non\u2013small-cell lung cancer (NADIM phase II trial). J Clin Oncol. 2022;40:2924\u201333.","journal-title":"J Clin Oncol"},{"key":"4305_CR35","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S1470-2045(24)00498-4","volume":"25","author":"M Provencio","year":"2024","unstructured":"Provencio M, Nadal E, Insa A, Garc\u00eda Campelo R, Casal J, D\u00f3mine M, et al. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024;25:1453\u201364.","journal-title":"Lancet Oncol"},{"key":"4305_CR36","doi-asserted-by":"publisher","first-page":"LBA8010","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8010","volume":"42","author":"J Spicer","year":"2024","unstructured":"Spicer J, Girard N, Provencio M, Wang C, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816. J Clin Oncol. 2024;42:LBA8010\u2013LBA8010.","journal-title":"J Clin Oncol"},{"key":"4305_CR37","doi-asserted-by":"publisher","unstructured":"Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, et al. Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer. N Engl J Med. 2025;393(8):741\u201352. https:\/\/doi.org\/10.1056\/NEJMoa2502931.","DOI":"10.1056\/NEJMoa2502931"},{"key":"4305_CR38","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","volume":"404","author":"JD Spicer","year":"2024","unstructured":"Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404:1240\u201352.","journal-title":"Lancet"},{"key":"4305_CR39","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, et al. Perioperative durvalumab for resectable non\u2013small-cell lung cancer. N Engl J Med. 2023;389:1672\u201384.","journal-title":"N Engl J Med"},{"key":"4305_CR40","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","volume":"390","author":"T Cascone","year":"2024","unstructured":"Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, et al. Perioperative nivolumab in resectable lung cancer. N Engl J Med. 2024;390:1756\u201369.","journal-title":"N Engl J Med"},{"key":"4305_CR41","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","volume":"13","author":"T Cascone","year":"2023","unstructured":"Cascone T, Kar G, Spicer JD, Garc\u00eda-Campelo R, Weder W, Daniel DB, et al. Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial. Cancer Discov. 2023;13:2394\u2013411.","journal-title":"Cancer Discov"},{"key":"4305_CR42","doi-asserted-by":"publisher","first-page":"LBA8035","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8035","volume":"42","author":"HA Wakelee","year":"2024","unstructured":"Wakelee HA, Altorki NK, Zhou C, Cs\u0151szi T, Vynnychenko IO, Goloborodko O, et al. IMpower010: final disease-free survival (DFS) and second overall survival (OS) interim results after \u22655 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB\u2013IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. 2024;42:LBA8035\u2013LBA8035.","journal-title":"J Clin Oncol"},{"key":"4305_CR43","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","volume":"23","author":"M O\u2019Brien","year":"2022","unstructured":"O\u2019Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB\u2013IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23:1274\u201386.","journal-title":"Lancet Oncol"},{"key":"4305_CR44","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer. N Engl J Med. 2017;377:1919\u201329.","journal-title":"N Engl J Med"},{"key":"4305_CR45","doi-asserted-by":"publisher","first-page":"103464","DOI":"10.1016\/j.esmoop.2024.103464","volume":"9","author":"AR Filippi","year":"2024","unstructured":"Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, et al. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R. ESMO Open. 2024;9:103464.","journal-title":"ESMO Open"},{"key":"4305_CR46","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.ijrobp.2021.12.150","volume":"112","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang T, Huang Y, Li W, Zhao J, Yang Y, et al. Real-world safety and efficacy of consolidation durvalumab after chemoradiation therapy for stage III non-small cell lung cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2022;112:1154\u201364.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4305_CR47","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2217\/imt-2023-0002","volume":"15","author":"MV Verschueren","year":"2023","unstructured":"Verschueren MV, Dijs T, Gulikers JL, van Veelen A, Croes S, Hendriks LEL, et al. Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results. Immunotherapy. 2023;15:839\u201351.","journal-title":"Immunotherapy"},{"key":"4305_CR48","doi-asserted-by":"crossref","unstructured":"J.D. Bradley SSKHHLGOADMZVSAGJJDMBZMNPCNJZFB-BM\u00d6 (2024) Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2","DOI":"10.1016\/j.esmoop.2024.102986"},{"key":"4305_CR49","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1001\/jamaoncol.2021.2301","volume":"7","author":"SK Jabbour","year":"2021","unstructured":"Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Pollock T, et al. Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage iii non-small cell lung cancer. JAMA Oncol. 2021;7:1351.","journal-title":"JAMA Oncol"},{"key":"4305_CR50","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1016\/j.cllc.2021.07.005","volume":"23","author":"D De Ruysscher","year":"2022","unstructured":"De Ruysscher D, Ramalingam S, Urbanic J, Gerber DE, Tan DSW, Cai J, et al. CheckMate 73L: a phase 3 study comparing nivolumab plus concurrent chemoradiotherapy followed by nivolumab with or without Ipilimumab versus concurrent chemoradiotherapy followed by durvalumab for previously untreated, locally advanced stage III non-small-cell lung cancer. Clin Lung Cancer. 2022;23:e264\u20138.","journal-title":"Clin Lung Cancer"},{"key":"4305_CR51","doi-asserted-by":"publisher","first-page":"10124","DOI":"10.1038\/s41467-025-66097-w","volume":"16","author":"M Provencio","year":"2025","unstructured":"Provencio M, Campos B, Guirado M, Vila L, Garc\u00eda Campelo R, Dorta M, et al. Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial. Nat Commun. 2025;16:10124. https:\/\/doi.org\/10.1038\/s41467-025-66097-w.","journal-title":"Nat Commun"},{"key":"4305_CR52","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.athoracsur.2010.03.042","volume":"90","author":"A Brunelli","year":"2010","unstructured":"Brunelli A, Varela G, Salati M, Jimenez MF, Pompili C, Novoa N, et al. Recalibration of the revised cardiac risk index in lung resection candidates. Ann Thorac Surg. 2010;90:199\u2013203.","journal-title":"Ann Thorac Surg"},{"issue":"17","key":"4305_CR53","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1161\/CIRCULATIONAHA.107.185700","volume":"116","author":"LA Fleisher","year":"2007","unstructured":"Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof EL, Fleischmann KE, et al. ACC\/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. Circulation. 2007;116(17):1971\u201396.","journal-title":"Circulation"},{"key":"4305_CR54","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1136\/thx.2010.145938","volume":"65","author":"E Lim","year":"2010","unstructured":"Lim E, Baldwin D, Beckles M, Duffy J, Entwisle J, Faivre-Finn C, et al. Guidelines on the radical management of patients with lung cancer. Thorax. 2010;65:iii1-27.","journal-title":"Thorax"},{"key":"4305_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1183\/09031936.00184308","volume":"34","author":"A Brunelli","year":"2009","unstructured":"Brunelli A, Charloux A, Bolliger CT, Rocco G, Sculier J-P, Varela G, et al. ERS\/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J. 2009;34:17\u201341.","journal-title":"Eur Respir J"},{"key":"4305_CR56","doi-asserted-by":"publisher","first-page":"e166S","DOI":"10.1378\/chest.12-2395","volume":"143","author":"A Brunelli","year":"2013","unstructured":"Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery. Chest. 2013;143:e166S-e190S.","journal-title":"Chest"},{"key":"4305_CR57","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.athoracsur.2009.12.065","volume":"89","author":"MF Berry","year":"2010","unstructured":"Berry MF, Villamizar-Ortiz NR, Tong BC, Burfeind WR, Harpole DH, D\u2019Amico TA, et al. Pulmonary function tests do not predict pulmonary complications after thoracoscopic lobectomy. Ann Thorac Surg. 2010;89:1044\u201352.","journal-title":"Ann Thorac Surg"},{"key":"4305_CR58","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.ejcts.2008.07.037","volume":"34","author":"MK Ferguson","year":"2008","unstructured":"Ferguson MK, Siddique J, Karrison T. Modeling major lung resection outcomes using classification trees and multiple imputation techniques. Eur J Cardiothorac Surg. 2008;34:1085\u20139.","journal-title":"Eur J Cardiothorac Surg"},{"key":"4305_CR59","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","volume":"28","author":"PE Postmus","year":"2017","unstructured":"Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv1-21.","journal-title":"Ann Oncol"},{"key":"4305_CR60","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fonc.2017.00249","volume":"7","author":"PE Van Schil","year":"2017","unstructured":"Van Schil PE, Berzenji L, Yogeswaran SK, Hendriks JM, Lauwers P. Surgical management of stage IIIA non-small cell lung cancer. Front Oncol. 2017;7:249.","journal-title":"Front Oncol"},{"key":"4305_CR61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.lungcan.2005.01.001","volume":"49","author":"R Rami-Porta","year":"2005","unstructured":"Rami-Porta R, Wittekind C, Goldstraw P. Complete resection in lung cancer surgery: proposed definition. Lung Cancer. 2005;49:25\u201333.","journal-title":"Lung Cancer"},{"key":"4305_CR62","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.jtho.2023.09.046","volume":"18","author":"A-M Dingemans","year":"2023","unstructured":"Dingemans A-M, Remon J, Hendriks L, Edwards J, Faivre-Finn C, Reguart N, et al. OA06.05 consensual definition of stage III NSCLC resectability: EORTC-lung cancer group initiative with other scientific societies. J Thorac Oncol. 2023;18:S57\u20138.","journal-title":"J Thorac Oncol"},{"key":"4305_CR63","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/SLA.0000000000001708","volume":"265","author":"H-X Yang","year":"2017","unstructured":"Yang H-X, Woo KM, Sima CS, Bains MS, Adusumilli PS, Huang J, et al. Long-term survival based on the surgical approach to lobectomy for clinical stage I nonsmall cell lung cancer. Ann Surg. 2017;265:431\u20137.","journal-title":"Ann Surg"},{"key":"4305_CR64","doi-asserted-by":"publisher","first-page":"101","DOI":"10.21037\/jtd-20-2251","volume":"13","author":"DA Dziedzic","year":"2021","unstructured":"Dziedzic DA, Zbytniewski M, Gryszko GM, Cackowski MM, Langfort R, Orlowski TM. Video-assisted versus open thoracotomy lobectomy: comparison on lymphadenectomy and survival in early stage of lung cancer. J Thorac Dis. 2021;13:101\u201312.","journal-title":"J Thorac Dis"},{"key":"4305_CR65","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jtho.2024.02.009","volume":"19","author":"P Ugalde Figueroa","year":"2024","unstructured":"Ugalde Figueroa P, Lacroix V, Van Schil PE. Neoadjuvant chemoimmunotherapy complicates subsequent surgical resection and adjuvant immunotherapy is preferable from the surgical standpoint. J Thorac Oncol. 2024;19:858\u201361.","journal-title":"J Thorac Oncol"},{"key":"4305_CR66","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.3390\/cancers16071302","volume":"16","author":"S Verma","year":"2024","unstructured":"Verma S, Breadner D, Mittal A, Palma DA, Nayak R, Raphael J, et al. An updated review of management of resectable stage III NSCLC in the era of neoadjuvant immunotherapy. Cancers (Basel). 2024;16:1302.","journal-title":"Cancers (Basel)"},{"key":"4305_CR67","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jtcvs.2023.09.073","volume":"167","author":"H Feldman","year":"2024","unstructured":"Feldman H, Sepesi B, Leung CH, Lin H, Weissferdt A, Pataer A, et al. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non\u2013small cell lung cancer. J Thorac Cardiovasc Surg. 2024;167:1444-1453.e4.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"4305_CR68","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1001\/jamaoncol.2023.2751","volume":"9","author":"J Lei","year":"2023","unstructured":"Lei J, Zhao J, Gong L, Ni Y, Zhou Y, Tian F, et al. Neoadjuvant camrelizumab plus platinum-based chemotherapy vs chemotherapy alone for Chinese patients with resectable stage IIIA or IIIB (T3N2) non\u2013small cell lung cancer. JAMA Oncol. 2023;9:1348.","journal-title":"JAMA Oncol"},{"key":"4305_CR69","doi-asserted-by":"publisher","first-page":"e964","DOI":"10.1634\/theoncologist.2019-0661","volume":"25","author":"M Behera","year":"2020","unstructured":"Behera M, Steuer CE, Liu Y, Fernandez F, Fu C, Higgins KA, et al. Trimodality therapy in the treatment of stage III N2-positive non-small cell lung cancer: a national cancer database analysis. Oncologist. 2020;25:e964\u201375.","journal-title":"Oncologist"},{"key":"4305_CR70","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/JTO.0b013e3181a0d82e","volume":"4","author":"VW Rusch","year":"2009","unstructured":"Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:568\u201377.","journal-title":"J Thorac Oncol"},{"key":"4305_CR71","doi-asserted-by":"publisher","first-page":"LBA8007","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8007","volume":"42","author":"M Provencio","year":"2024","unstructured":"Provencio M, Awad MM, Spicer J, Janssens A, Moiseenko FV, Gao Y, et al. Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: results from the phase 3 CheckMate 77T study. J Clin Oncol. 2024;42:LBA8007\u2013LBA8007.","journal-title":"J Clin Oncol"},{"key":"4305_CR72","doi-asserted-by":"publisher","unstructured":"Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, et al. SAKK 16\/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non\u2013Small-Cell Lung Cancer\u2014A Multicenter Single-Arm Phase II Trial. J Clin Oncol. 2021;39(26):2872\u201380. https:\/\/doi.org\/10.1200\/JCO.21.00276.","DOI":"10.1200\/JCO.21.00276"},{"key":"4305_CR73","doi-asserted-by":"publisher","unstructured":"Cascone T, William WN Jr, Weissferdt A, Leung CH, Lin HY, Pataer A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021;27(3):504\u201314. https:\/\/doi.org\/10.1038\/s41591-020-01224-2.","DOI":"10.1038\/s41591-020-01224-2"},{"key":"4305_CR74","doi-asserted-by":"publisher","unstructured":"Rusch VW, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura EB, et al. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non\u2013small cell lung cancer. J Thorac Cardiovasc Surg. 2023;165(3):828\u201339.e5. https:\/\/doi.org\/10.1016\/j.jtcvs.2022.10.007.","DOI":"10.1016\/j.jtcvs.2022.10.007"},{"key":"4305_CR75","doi-asserted-by":"publisher","unstructured":"Mitsudomi T, Heymach JV, Reck M, Taube JM, Gao S, Horio Y, et al. Surgical outcomes with neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in resectable NSCLC. J Thorac Oncol. 2025;20(11):1639\u201354. https:\/\/doi.org\/10.1016\/j.jtho.2025.06.015.","DOI":"10.1016\/j.jtho.2025.06.015"},{"key":"4305_CR76","unstructured":"Jorge Humberto Rodriguez-Quintero RZMKRJMVNCBS (2024) Outcomes of patients with cT3-4N2 NSCLC in the era of modern systemic therapy. Is it time to redefine respectability? 60th Annual Meeting of The Society of Thoracic Surgeons"},{"key":"4305_CR77","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/j.jtcvs.2023.09.029","volume":"167","author":"A Kumar","year":"2024","unstructured":"Kumar A, Srinivasan D, Potter AL, Mathey-Andrews C, Lanuti M, Martin LW, et al. Induction chemoimmunotherapy with surgery versus concurrent chemoradiation followed by immunotherapy for stage III-N2 non\u2013small cell lung cancer. J Thorac Cardiovasc Surg. 2024;167:1895-1905.e2.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"4305_CR78","doi-asserted-by":"publisher","first-page":"41670","DOI":"10.18632\/oncotarget.16471","volume":"8","author":"C P\u00f6ttgen","year":"2017","unstructured":"P\u00f6ttgen C, Eberhardt W, Stamatis G, Stuschke M. Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC)\u2014a cumulative meta-analysis of the randomized evidence. Oncotarget. 2017;8:41670\u20138.","journal-title":"Oncotarget"},{"key":"4305_CR79","doi-asserted-by":"publisher","first-page":"00159","DOI":"10.1183\/23120541.00159-2019","volume":"6","author":"PM Putora","year":"2020","unstructured":"Putora PM, Leskow P, McDonald F, Batchelor T, Evison M. International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? ERJ Open Res. 2020;6:00159\u20132019.","journal-title":"ERJ Open Res"},{"key":"4305_CR80","doi-asserted-by":"publisher","first-page":"S292","DOI":"10.1016\/j.jtho.2023.09.502","volume":"18","author":"M Brandao","year":"2023","unstructured":"Brandao M, Prisciandaro E, Xenophontos E, Mariolo A, Sadeghi AH, Filippi AR, et al. P1.28-09 definition of resectable stage III non-small cell lung cancer (NSCLC): a clinical case review by a Pan-European expert panel. J Thorac Oncol. 2023;18:S292\u20133.","journal-title":"J Thorac Oncol"},{"key":"4305_CR81","doi-asserted-by":"publisher","first-page":"100410","DOI":"10.1016\/j.esmoop.2022.100410","volume":"7","author":"S Senan","year":"2022","unstructured":"Senan S, \u00d6zg\u00fcro\u011flu M, Daniel D, Villegas A, Vicente D, Murakami S, et al. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial. ESMO Open. 2022;7:100410.","journal-title":"ESMO Open"},{"key":"4305_CR82","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.cllc.2016.01.007","volume":"17","author":"N Jegadeesh","year":"2016","unstructured":"Jegadeesh N, Liu Y, Gillespie T, Fernandez F, Ramalingam S, Mikell J, et al. Evaluating intensity-modulated radiation therapy in locally advanced non\u2013small-cell lung cancer: results from the National Cancer Data Base. Clin Lung Cancer. 2016;17:398\u2013405.","journal-title":"Clin Lung Cancer"},{"key":"4305_CR83","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.radonc.2022.01.039","volume":"168","author":"DS M\u00f8ller","year":"2022","unstructured":"M\u00f8ller DS, Lutz CM, Khalil AA, Alber M, Holt MI, Kandi M, et al. Survival benefits for non-small cell lung cancer patients treated with adaptive radiotherapy. Radiother Oncol. 2022;168:234\u201340.","journal-title":"Radiother Oncol"},{"key":"4305_CR84","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jtho.2023.02.009","volume":"18","author":"J Naidoo","year":"2023","unstructured":"Naidoo J, Antonia S, Wu Y-L, Cho BC, Thiyagarajah P, Mann H, et al. Brief report: durvalumab after chemoradiotherapy in unresectable stage III EGFR-Mutant NSCLC: a post hoc subgroup analysis from PACIFIC. J Thorac Oncol. 2023;18:657\u201363.","journal-title":"J Thorac Oncol"},{"key":"4305_CR85","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13014-022-02080-9","volume":"17","author":"N Guberina","year":"2022","unstructured":"Guberina N, P\u00f6ttgen C, Schuler M, Guberina M, Stamatis G, Pl\u00f6nes T, et al. Long-term survival of patients with central or> 7 cm T4 N0\/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment. Radiat Oncol. 2022;17:126.","journal-title":"Radiat Oncol"},{"issue":"3","key":"4305_CR86","doi-asserted-by":"publisher","first-page":"e501","DOI":"10.1002\/mco2.501","volume":"5","author":"L Wu","year":"2024","unstructured":"Wu L, Cheng B, Sun X, Zhang Z, Kang J, Chen Y, et al. Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non-small cell lung cancer: a multi-institutional retrospective cohort study. MedComm (Beijing). 2024;5(3):e501.","journal-title":"MedComm (Beijing)"},{"key":"4305_CR87","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.annonc.2025.08.003","volume":"36","author":"A Zer","year":"2025","unstructured":"Zer A, Ahn M-J, Barlesi F, Bubendorf L, De Ruysscher D, Garrido P, et al. Early and locally advanced non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36:1245\u201362.","journal-title":"Ann Oncol"},{"key":"4305_CR88","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.21037\/tlcr-2025-619","volume":"14","author":"AV Ospina-Serrano","year":"2025","unstructured":"Ospina-Serrano AV, Gonz\u00e1lez-Larriba JL, Nadal E, Trancho FH, Bosch-Barrera J, Calvo V, et al. Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish lung cancer group (GECP) expert consensus statement. Trans Lung Cancer Res. 2025;14:3299\u2013322.","journal-title":"Trans Lung Cancer Res"},{"key":"4305_CR89","doi-asserted-by":"publisher","first-page":"113404","DOI":"10.1016\/j.ejca.2023.113404","volume":"195","author":"A Nuccio","year":"2023","unstructured":"Nuccio A, Viscardi G, Salomone F, Servetto A, Venanzi FM, Riva ST, et al. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: impact of clinicopathological factors and indirect comparison between treatment strategies. Eur J Cancer. 2023;195:113404.","journal-title":"Eur J Cancer"},{"key":"4305_CR90","doi-asserted-by":"publisher","first-page":"102833","DOI":"10.1016\/j.ctrv.2024.102833","volume":"131","author":"R Aburaki","year":"2024","unstructured":"Aburaki R, Fujiwara Y, Chida K, Horita N, Nagasaka M. Surgical and safety outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: a systematic review and meta-analysis. Cancer Treat Rev. 2024;131:102833.","journal-title":"Cancer Treat Rev"},{"key":"4305_CR91","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1200\/JCO.2024.42.16_suppl.8008","volume":"42","author":"H Liu","year":"2024","unstructured":"Liu H, Qiu B, Zhao Y, He W, Feng W, Zeng W, et al. A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091). J Clin Oncol. 2024;42:8008\u20138008.","journal-title":"J Clin Oncol"},{"key":"4305_CR92","doi-asserted-by":"crossref","unstructured":"William WN, Junior GC, Matias D d. A, Ara\u00fajo LH d. L, Reis TV, Teixeira VBG, et al (2024) OA12.06 intensified chemo-immuno-radiotherapy with durvalumab for stage III NSCLCs: a single arm phase II study\u2014PACIFIC-BRAZIL (LACOG 2218). J Thorac Oncol 19:S37\u2013S38.","DOI":"10.1016\/j.jtho.2024.09.068"},{"key":"4305_CR93","doi-asserted-by":"publisher","first-page":"8513","DOI":"10.1200\/JCO.2021.39.15_suppl.8513","volume":"39","author":"HJ Ross","year":"2021","unstructured":"Ross HJ, Kozono DE, Urbanic JJ, Williams TM, DuFrane C, Bara I, et al. AFT-16: phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39:8513\u20138513.","journal-title":"J Clin Oncol"},{"key":"4305_CR94","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00262-024-03696-4","volume":"73","author":"S Guan","year":"2024","unstructured":"Guan S, Sun J, Wang Y, Han S, Chen C, Yue D, et al. Chemoradiotherapy versus surgery after neoadjuvant chemoimmunotherapy in patients with stage III NSCLC: a real-world multicenter retrospective study. Cancer Immunol Immunother. 2024;73:120.","journal-title":"Cancer Immunol Immunother"},{"key":"4305_CR95","doi-asserted-by":"publisher","first-page":"107884","DOI":"10.1016\/j.lungcan.2024.107884","volume":"194","author":"R Li","year":"2024","unstructured":"Li R, Xu Y, Zhao J, Zhang L, Zhong W, Gao X, et al. Comparison of radiotherapy versus surgical resection following neoadjuvant chemoimmunotherapy in potentially resectable stage III non-small-cell lung cancer: a propensity score matching analysis. Lung Cancer. 2024;194:107884.","journal-title":"Lung Cancer"},{"key":"4305_CR96","unstructured":"Jorge Humberto Rodriguez-Quintero RZMKRJMVNCBS (2023) Improved outcomes with systemic therapy following R+ resections for non-small cell lung cancer in a contemporary multicentric cohort of patients. International Thoracic Surgical Oncology Summit."},{"key":"4305_CR97","doi-asserted-by":"publisher","first-page":"S1721","DOI":"10.1016\/j.annonc.2025.09.077","volume":"36","author":"M Reck","year":"2025","unstructured":"Reck M, Girard N, Nadal E, Gay CM, Filippi AR, Martin LW, et al. LBA65 neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB\u2013IIIB NSCLC: interim analysis (IA) of the phase II MDT-BRIDGE study. Ann Oncol. 2025;36:S1721\u20132.","journal-title":"Ann Oncol"},{"key":"4305_CR98","doi-asserted-by":"publisher","first-page":"e009799","DOI":"10.1136\/jitc-2024-009799","volume":"12","author":"I Bahce","year":"2024","unstructured":"Bahce I, Dickhoff C, Schneiders FL, Veltman J, Heineman DJ, Hashemi SMS, et al. Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study. J Immunother Cancer. 2024;12:e009799.","journal-title":"J Immunother Cancer"},{"key":"4305_CR99","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1097\/SLA.0000000000005233","volume":"275","author":"H Deng","year":"2022","unstructured":"Deng H, Liu J, Cai X, Chen J, Rocco G, Petersen RH, et al. Radical minimally invasive surgery after immuno-chemotherapy in initially-unresectable stage IIIB non-small cell lung cancer. Ann Surg. 2022;275:e600\u20132.","journal-title":"Ann Surg"},{"key":"4305_CR100","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.ccell.2024.05.024","volume":"42","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Pan Y, Yang X, Zhao Y, Han G, Pang Q, et al. Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: a proof-of-concept, phase 2 trial. Cancer Cell. 2024;42:1258-1267.e2.","journal-title":"Cancer Cell"},{"key":"4305_CR101","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaoncol.2025.1115","volume":"11","author":"B Ricciuti","year":"2025","unstructured":"Ricciuti B, Fusco F, Cooper A, Garbo E, Pecci F, Aldea M, et al. Neoadjuvant PD-1 and PD-L1 blockade with chemotherapy for borderline resectable and unresectable stage III non-small cell lung cancer. JAMA Oncol. 2025;11:735\u201341.","journal-title":"JAMA Oncol"},{"key":"4305_CR102","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30:1321\u20138.","journal-title":"Ann Oncol"},{"key":"4305_CR103","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.jtho.2023.09.071","volume":"18","author":"J He","year":"2023","unstructured":"He J, Gao S, Reck M, Harpole D, Mitsudomi T, Taube JM, et al. Neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in resectable EGFR-mutated NSCLC (AEGEAN). J Thorac Oncol. 2023;18:S72\u20133.","journal-title":"J Thorac Oncol"},{"key":"4305_CR104","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","volume":"389","author":"M Tsuboi","year":"2023","unstructured":"Tsuboi M, Herbst RS, John T, Kato T, Majem M, Groh\u00e9 C, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med. 2023;389:137\u201347.","journal-title":"N Engl J Med"},{"key":"4305_CR105","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","volume":"390","author":"Y-L Wu","year":"2024","unstructured":"Wu Y-L, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, et al. Alectinib in resected ALK-positive non\u2013small-cell lung cancer. N Engl J Med. 2024;390:1265\u201376.","journal-title":"N Engl J Med"},{"key":"4305_CR106","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.lungcan.2023.02.011","volume":"178","author":"C Lv","year":"2023","unstructured":"Lv C, Fang W, Wu N, Jiao W, Xu S, Ma H, et al. Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II\u2013IIIB lung adenocarcinoma (NEOS): a multicenter, single-arm, open-label phase 2b trial. Lung Cancer. 2023;178:151\u20136.","journal-title":"Lung Cancer"},{"key":"4305_CR107","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO-25-00883","volume":"43","author":"J He","year":"2025","unstructured":"He J, Tsuboi M, Weder W, Chen K-N, Hochmair MJ, Shih J-Y, et al. Neoadjuvant osimertinib for resectable EGFR-mutated non-small cell lung cancer. J Clin Oncol. 2025;43:2875\u201387.","journal-title":"J Clin Oncol"},{"key":"4305_CR108","doi-asserted-by":"publisher","first-page":"8015","DOI":"10.1200\/JCO.2025.43.16_suppl.8015","volume":"43","author":"A Leonetti","year":"2025","unstructured":"Leonetti A, Boni L, Gnetti L, Cortinovis DL, Pasello G, Mazzoni F, et al. Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: final analysis of ALNEO phase II trial (GOIRC-01-2020-ML42316). J Clin Oncol. 2025;43:8015\u20138015.","journal-title":"J Clin Oncol"},{"key":"4305_CR109","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2402614","volume":"391","author":"S Lu","year":"2024","unstructured":"Lu S, Kato T, Dong X, Ahn M-J, Quang L-V, Soparattanapaisarn N, et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med. 2024;391:585\u201397.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04305-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04305-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04305-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:02:58Z","timestamp":1790164978000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04305-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":109,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4305"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04305-9","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Xabier Mielgo-Rubio has served as member of board of directors for cooperative groups GETICA and GETTHI, has provided consultancy services for MSD, Regeneron, BMS, Boehringer Ingelheim, Pfizer, Takeda, Roche, and AstraZeneca, has received a research grant from BMS, has received fees for educational presentations from Novartis, MSD, BMS, Roche, AstraZeneca, Pfizer, Takeda, and Ferrer, and has received travel\/accommodation support from Roche, Johnson & Johnson, Pierre Fabre, MSD, BMS, Lilly, and Pfizer. Virginia Calvo De Juan reports consulting fees from Roche, AstraZeneca, MSD, BMS, Takeda, Sanofi, Amgen, GSK, Boehringer Ingelheim, and Janssen; honoraria for lectures from Roche, AstraZeneca, MSD, BMS, Takeda, Sanofi, Amgen, Pfizer, Janssen, and Beigene; and support for attending meetings from AstraZeneca, Roche, MSD, Takeda, and Janssen. Rafael L\u00f3pez Castro has received travel\/accommodation support from MSD and AstraZeneca. Mariano Provencio Pulla reports grants, consulting fees, and non-financial support from Bristol Myers Squibb, Roche, and AstraZeneca, and consulting fees from MSD and Takeda. Felipe Cou\u00f1ago has served on advisory boards for AstraZeneca and J&J, has provided consultancy services for AstraZeneca and J&J, has received honoraria, manuscript preparation fees, and fees for educational presentations from Accord, Astellas, AstraZeneca, Bayer, Ipssen, J&J, Recordati, and Roche Farma, and has received travel\/accommodation support from Astellas, AstraZeneca, Bayer, J&J, Recordati, and Roche Farma. Rest of authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this review article, as it does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was not required for this review article because no individual patient data are included.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}